Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm
Female
Humans
Lung Neoplasms
Male
Middle Aged
National Cancer Institute (U.S.)
Neoplasm Recurrence, Local
Neoplasm Staging
Quinazolines
Receptors, Vascular Endothelial Growth Factor
Salvage Therapy
Small Cell Lung Carcinoma
Survival Rate
Treatment Outcome
United States

authors with profiles

Everett E. Vokes